[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368251-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368251-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","microsatellite-instability-high-status-as-a-pan-cancer-biomarker-for-immunotherapy-efficacy","Microsatellite instability‑high status as a pan‑cancer biomarker for immunotherapy efficacy","","Microsatellite instability-high (MSI-H) cancers show exceptional benefit from immune checkpoint inhibitors, yet evidence for immunotherapy efficacy across diverse MSI-H cancer types remains limited. A systematic review and meta-analysis of randomized clinical trials compared immune checkpoint inhibitors with chemotherapy in advanced MSI-H/dMMR disease, including 13 RCTs and 1633 patients. Results demonstrated significant improvements in progression-free and overall survival, with consistent subgroup benefits across colorectal, gastric, and endometrial cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/microsatellite-instability-high-status-as-a-pan-cancer-biomarker-for-immunotherapy-efficacy/368251/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/microsatellite-instability-high-status-as-a-pan-cancer-biomarker-for-immunotherapy-efficacy/368251.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of this study?","Question",{"text":63,"@type":64},"To evaluate whether microsatellite instability-high (MSI-H) status can serve as a pan-cancer predictive biomarker for immune checkpoint inhibitor efficacy across different MSI-H/dMMR cancer types.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were eligible studies selected?",{"text":68,"@type":64},"Randomized clinical trials comparing immunotherapy-containing treatments with chemotherapy in advanced MSI-H/dMMR tumors were included, provided they reported overall survival or progression-free survival; retrospective, Phase I, and single-arm Phase II studies were excluded.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes improved for MSI-H patients treated with immunotherapy?",{"text":72,"@type":64},"Immunotherapy significantly improved progression-free survival and overall survival, including an overall survival hazard ratio of 0.35 for MSI-H patients versus 0.81 for MSS patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368251,1790322737,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Cancer Immunology, Immunotherapy (2025) 74:122 [https://doi.org/10.1007/s00262-025-03980-x](https://doi.org/10.1007/s00262-025-03980-x)  \nMicrosatellite instability‑high status as a pan‑cancer biomarker for immunotherapy efficacy  \nThierry Landre1 · Gaëtan Des Guetz2  \nReceived: 10 January 2025 / Accepted: 11 February 2025 / Published online: 25 February 2025 © The Author(s) 2025  \nAbstract  \nBackground Microsatellite instability-high (MSI-H) cancers are linked to exceptional benefit from immune checkpoint inhibitors (ICIs), but studies on their efficacy across various MSI-H cancer types are limited.  \nMethods Randomized clinical trials (RCTs) comparing ICIs to chemotherapy in advanced MSI-H/dMMR cancers were systematically reviewed. Eligible studies included 13 RCTs with 1633 MSI-H patients across colorectal, gastric, and endometrial cancers. Data were analyzed using hazard ratios for progression-free survival (PFS) and overall survival (OS), with subgroup analyses by tumor type. Statistical heterogeneity was assessed using Cochrane’s Q and I2.  \nResults Immunotherapy significantly improved PFS and OS in MSI-H patients, with an HR for OS of 0.35 (95% CI 0.27– 0.46; p \u003C 0.00001) versus 0.81 for MSS patients. PFS showed a 64% reduced risk of progression (HR = 0.36, 95% CI 0.28– 0.46; p \u003C 0.0001). Subgroup analyses highlighted PFS benefits across tumor types: colorectal (HR = 0.28, 95% CI 0.11–0.73), gastric (HR = 0.43, 95% CI 0.27–0.68), and endometrial cancers (HR = 0.34, 95% CI 0.27–0.42) .  \nConclusions This meta-analysis establishes MSI-H as a predictive biomarker for ICIs, supporting its role in therapy selection and underscoring the need for MSI-H/dMMR-focused clinical trials.  \nKeywords Microsatellite instability-high · Immune checkpoint inhibitors · Meta-analysis · Randomized trials · Overall survival  \nIntroduction  \nImmunotherapy represents a major breakthrough in cancer treatment, particularly for tumors with microsatellite instability (MSI) or a mismatch repair deficiency (dMMR) . The prevalence of MSI varies depending on the cancer type: 17–33% of endometrial cancers, 9–22% of gastric cancers, and 6–13% of colorectal cancers and with lower frequencies in other cancers (e.g., bladder, prostate, breast, renal cell carcinoma, pancreas, small cell lung cancer, thyroid, sarcomas)  \n[1]. The prognosis of these advanced cancers has historically  \n* Thierry Landre [thierry.landre@aphp.fr](thierry.landre@aphp.fr)  \n1 Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital René Muret, Hôpitaux Universitaires de Paris Seine-StDenis, Avenue du Dr Schaeffner, 93270 Sevran, France  \n2 Service d’Oncologie Médicale, Faculté de Médecine, Centre Hospitalier de St-Denis, Université Sorbonne Paris Nord, St-Denis, France  \nbeen poor due to resistance to conventional treatments such as chemotherapy [2, 3] .  \nEarly-phase clinical trials demonstrated that immune checkpoint inhibitors, such as anti-PD-1 and anti-PDL1 therapies, revolutionized the management of these patients [4] . Anti-PD-1 therapies, like pembrolizumab and nivolumab, have shown remarkable efficacy in patients with MSI/dMMR cancers, yielding consistently high response rates and significant improvements in overall survival (OS), even at the metastatic stage.  \nIn randomized immunotherapy trials for advanced cancers, very few focus specifically on MSI/dMMR patients. However, subgroup analyses of these studies show the substantial contribution of immunotherapy in gastroesophageal and gynecological cancers. Current studies and associated indications do not differentiate the role of microsatellite instability as a response marker. It appears both useful and necessary to conduct a meta-analysis of published randomized trials to better understand the benefit of immunotherapy across all MSI tumors, whether associated with Lynch syndrome or sporadic MSI.  \nMethodology  \nSearch strategy and inclusion criteria  \nFor this study, a systematic search was conducted in the Embase, Medline","cbCaii0uMBjpvKP8","https://ap.wps.com/l/cbCaii0uMBjpvKP8","pdf",821381,"English","# Abstract\n# Introduction\n# Methodology\n## Search strategy and inclusion criteria\n## Statistical analysis\n## Study selection and data extraction\n# Results\n# Conclusions","[{\"question\":\"What is the main objective of this study?\",\"answer\":\"To evaluate whether microsatellite instability-high (MSI-H) status can serve as a pan-cancer predictive biomarker for immune checkpoint inhibitor efficacy across different MSI-H/dMMR cancer types.\"},{\"question\":\"How were eligible studies selected?\",\"answer\":\"Randomized clinical trials comparing immunotherapy-containing treatments with chemotherapy in advanced MSI-H/dMMR tumors were included, provided they reported overall survival or progression-free survival; retrospective, Phase I, and single-arm Phase II studies were excluded.\"},{\"question\":\"What outcomes improved for MSI-H patients treated with immunotherapy?\",\"answer\":\"Immunotherapy significantly improved progression-free survival and overall survival, including an overall survival hazard ratio of 0.35 for MSI-H patients versus 0.81 for MSS patients.\"}]","Microsatellite instability‑high status as a pan‑cancer biomarker for immunotherapy efficacy | PDF",1790175864,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b229816da987767f96f0ba7557a5083.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd581ad20b0c31826c08148ea7c28894.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd763c9d8855e2f4103c8f53e245acd9.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45c1fa82fb461de986a428419210c9dd.webp",980,1301]